BIT Capital’s MacroGenics MGNX Stock Holding History

BIT Capital’s Portfolio MGNX Stock Details MGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-15,902	Closed	-$153K	–	124
2023 Q4	$153K	Buy	+15,902	New	+$110K	0.02%	78

Other funds holding MGNX

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BIT Capital's MGNX Position: Q1 2024 in Review

BIT Capital sold out of MacroGenics (MGNX) in Q1 2024, closing a stake of 15,902 shares — an estimated $153K sold.

BIT Capital first reported a position in MGNX in Q4 2023 and held it in 1 quarter. The position peaked at $153K in Q4 2023. 163 funds tracked by Wall St. Rank hold MGNX as of Q1 2024.

BIT Capital reported no remaining MacroGenics position as of Q1 2024 after selling out during the quarter.
BIT Capital sold 15,902 MacroGenics shares in Q1 2024, an estimated $153K.
BIT Capital first reported a position in MacroGenics in Q4 2023 and held it in 1 quarter.
BIT Capital's MacroGenics position peaked at $153K in Q4 2023.
163 funds tracked by Wall St. Rank held MacroGenics as of Q1 2024.

Based on BIT Capital's 13F filing for Q1 2024, filed 12 Feb 2025.